|Mr. Patrick J. Mahaffy||Co-Founder, CEO, Pres & Exec. Director||1.14M||N/A||1963|
|Dr. Gillian C. Ivers-Read||Co-Founder, Chief Regulatory Officer & Exec. VP of Technical Operations||689.09k||N/A||1954|
|Mr. Daniel W. Muehl||Sr. VP of Fin., Principal Financial Officer & Principal Accounting Officer||605.38k||N/A||1964|
|Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM||Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance and Chief Medical Officer||N/A||N/A||1968|
|Mr. Corwin Dale Hooks||Sr. VP & Chief Commercial Officer||693.65k||N/A||1967|
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company's product candidates include lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors; and rociletinib, an oral mutant-selective inhibitor of epidermal growth factor receptor. It distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; collaboration and license agreement with Les Laboratoires Servier; a clinical collaboration with Bristol-Myers Squibb Company; a partnership with Foundation Medicine, Inc; and a diagnostic collaboration with Myriad Genetics, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Clovis Oncology, Inc.’s ISS Governance QualityScore as of November 1, 2018 is 8. The pillar scores are Audit: 10; Board: 2; Shareholder Rights: 8; Compensation: 10.